Skip to main content

Governance

Supporting Investor Confidence

At Illumina, Inc., our Board of Directors and management believe that good corporate governance is an important component in enhancing investor confidence in the Company and increasing stockholder value. The imperative to continue to develop and implement best practices throughout our corporate governance structure is fundamental to our strategy to enhance performance by creating an environment that increases operational efficiency and ensures long-term productivity and growth. Sound corporate governance practices also ensure alignment with stockholder interests by promoting fairness, transparency, and accountability in business activities among employees, management, and the Board of Directors.

The corporate governance guidelines, along with the Code of Conduct*, charters of each of the Board Committees and the key practices of the Board of Directors provide the framework for corporate governance at Illumina, Inc.

Corporate Governance

* On May 24, 2022, the Code of Conduct (the “Code”) was amended to (i) add language regarding patient advocacy, clinical research and the patient-physician relationship, (ii) require that managers are responsible for conveying any concern relating to conduct that may violate the law, Company policies or procedures, or the Code, to the Chief Compliance Officer or other senior member of the Compliance Department within forty-eight (48) hours, and (iii) make clear that every individual covered by the Code is responsible to fully cooperate with any investigation being carried out by or on behalf of Illumina, and employees who fail to cooperate may be subject to disciplinary action. On October 30, 2019, the Code of Conduct (the “Code”) was amended to (1) prohibit employees from investing in pre-IPO companies that are currently or were formerly part of Illumina’s Accelerator program and (2) clarify that permission for limited personal use of Company assets applies only to information technology resources. On April 30, 2020, the Code was amended to (1) clarify that Illumina’s Compliance department must review any potential conflict of interest and that manager approval is insufficient, (2) align the Code with Illumina’s updated Corporate Privacy Policy, (3) add language describing Illumina’s efforts to address human rights and corporate social responsibility, and (4) correct references, contact information and other minor typographical errors.